{"id":"baxdrostat-and-dapagliflozin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Volume depletion"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Baxdrostat is a non-steroidal aldosterone synthase inhibitor that decreases aldosterone levels, reducing sodium retention and blood pressure while improving cardiac function. Dapagliflozin is an SGLT2 inhibitor that promotes urinary glucose excretion and has cardioprotective and renoprotective effects. The combination targets complementary pathways in cardiometabolic disease.","oneSentence":"Baxdrostat inhibits aldosterone synthase to reduce aldosterone production, while dapagliflozin inhibits SGLT2 to increase urinary glucose excretion, together addressing both hypertension/heart failure and glycemic control.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:21.222Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction"},{"name":"Hypertension with cardiometabolic disease"}]},"trialDetails":[{"nctId":"NCT06742723","phase":"PHASE3","title":"A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-03","conditions":"Chronic Kidney Disease and Hypertension","enrollment":5000},{"nctId":"NCT07222917","phase":"PHASE2","title":"A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-05","conditions":"Chronic Kidney Disease and Hypertension","enrollment":218},{"nctId":"NCT06677060","phase":"PHASE3","title":"Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-14","conditions":"Heart Failure","enrollment":11300},{"nctId":"NCT06268873","phase":"PHASE3","title":"A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-29","conditions":"Chronic Kidney Disease and Hypertension","enrollment":2554}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Baxdrostat CIN-107"],"phase":"phase_3","status":"active","brandName":"Baxdrostat and dapagliflozin","genericName":"Baxdrostat and dapagliflozin","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Baxdrostat is being studied in combination with dapagliflozin for the treatment of Chronic Kidney Disease and Hypertension, as well as Heart Failure. Dapagliflozin, when combined with Baxdrostat, is being evaluated for its effect on albuminuria in participants with Chronic Kidney Disease and high blood pressure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}